| Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|---|
Hazard ratio | 95% CI | p-value | Hazard ratio | 95% CI | p-value | |
All breast cancer (n = 55) | ||||||
 Age (≤ 56) | 0.639 | 0.301–1.331 | 0.231 | 0.369 | 0.076–1.337 | 0.135 |
 Menopause (−) | 0.651 | 0.289–1.380 | 0.268 | 1.936 | 0.518–9.476 | 0.340 |
 Tumor size (> 2) | 2.262 | 0.666–14.138 | 0.216 | 5.534 | 1.251–39.387 | 0.023 |
 Lymph node (+) | 0.760 | 0.288–2.611 | 0.627 | 0.295 | 0.083–1.207 | 0.086 |
 Nuclear grade (3) | 1.308 | 0.516–2.921 | 0.547 | 0.751 | 0.256–2.016 | 0.577 |
 Ki67 (> 14) | 1.797 | 0.859–3.881 | 0.120 | 2.606 | 1.028–6.780 | 0.044 |
 Pathological response (non-pCR) | 3.321 | 1.264–11.437 | 0.013 | 4.355 | 1.438–16.871 | 0.008 |
 Metastasis site (distant) | 1.415 | 0.666–2.950 | 0.359 | 2.496 | 1.007–6.126 | 0.048 |
 Relapse-free survival (< 2 years) | 2.439 | 1.005–7.269 | 0.049 | 1.938 | 0.681–6.598 | 0.225 |
Luminal (n = 23) | ||||||
 Age (≤ 56) | 1.228 | 0.382–3.948 | 0.724 | 5.415 | 0.194–115.713 | 0.275 |
 Menopause (−) | 1.252 | 0.369–3.941 | 0.704 | 1.614 | 0.104–46.371 | 0.736 |
 Tumor size (> 2) | 6.235 × 107 | 0.822–0.822 | 0.073 | 3.108 × 109 | 1.662–7.5 × 10179 | 0.024 |
 Lymph node (+) | 5.733 × 107 | 0.561–0.561 | 0.135 | 1.772 × 1010 | 1.806–unparsable | 0.028 |
 Nuclear grade (3) | 1.198 | 0.265–4.042 | 0.791 | 0.436 | 0.034–4.914 | 0.477 |
 Ki67 (> 14) | 1.118 | 0.345–3.648 | 0.849 | 0.982 | 0.180–4.386 | 0.982 |
 Pathological response (non-pCR) | 7.144 | 1.358–131.592 | 0.016 | 300.204 | 7.824–52,372.311 | < 0.001 |
 Metastatic site (distant) | 2.520 | 0.740–7.971 | 0.132 | 15.037 | 2.182–159.623 | 0.005 |
 Relapse-free survival (< 2 years) | 2.175 | 0.647–9.825 | 0.219 | 0.165 | 0.012–2.177 | 0.160 |
TNBC (n = 20) | ||||||
 Age (≤ 56) | 0.936 | 0.291–3.018 | 0.910 | 0.578 | 0.011–20.101 | 0.759 |
 Menopause (−) | 1.025 | 0.299–3.258 | 0.967 | 0.919 | 0.022–36.398 | 0.962 |
 Tumor size (> 2) | 0.948 | 0.222–6.663 | 0.949 | 2.141 | 0.100–93.753 | 0.639 |
 Lymph node (+) | 0.507 | 0.133–2.415 | 0.360 | 1.083 | 0.049–53.468 | 0.963 |
 Nuclear grade (3) | 1.841 | 0.479–6.155 | 0.350 | 0.109 | 0.003–1.421 | 0.094 |
 Ki67 (> 14) | 4.242 | 1.078–28.056 | 0.038 | 51.171 | 1.769–4346.194 | 0.020 |
 Pathological response (non-pCR) | 2.110 | 0.547–13.871 | 0.303 | 1.813 | 0.045–56.645 | 0.733 |
 Metastatic site (distant) | 1.569 | 0.486–5.070 | 0.442 | 13.318 | 1.021–540.473 | 0.048 |
 Relapse-free survival (< 2 years) | 7.070 × 107 | 0.812–0.812 | 0.074 | 2.294 × 107 | 0.027–3.0 × 10289 | 0.454 |